Puma Biotechnology (NASDAQ:PBYI) Posts Earnings Results, Beats Expectations By $0.29 EPS

Puma Biotechnology (NASDAQ:PBYI) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.39 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.29, Zacks reports. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The firm had revenue of $59.10 million for the quarter, compared to analysts’ expectations of $52.50 million. Puma Biotechnology updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Puma Biotechnology Stock Up 16.7 %

Shares of NASDAQ PBYI traded up $0.50 during midday trading on Friday, reaching $3.49. 1,316,096 shares of the company’s stock traded hands, compared to its average volume of 544,710. Puma Biotechnology has a one year low of $2.22 and a one year high of $7.15. The stock’s 50 day simple moving average is $3.00 and its 200-day simple moving average is $2.86. The company has a market cap of $171.32 million, a price-to-earnings ratio of 7.17 and a beta of 1.09. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46.

Insider Transactions at Puma Biotechnology

In other news, insider Jeffrey Jerome Ludwig sold 9,437 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total transaction of $29,726.55. Following the transaction, the insider now directly owns 108,951 shares of the company’s stock, valued at approximately $343,195.65. This represents a 7.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Alan H. Auerbach sold 33,841 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $106,599.15. Following the transaction, the chief executive officer now directly owns 7,029,674 shares in the company, valued at $22,143,473.10. This represents a 0.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 23.70% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on PBYI shares. StockNews.com lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 6th. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Puma Biotechnology in a report on Friday.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.